micro-community-banner
  • Saved

1yr
Erythroderma combined with deeper dermal dermatophytosis due to Trichophyton rubrum in a patient with myasthenia gravis: first case report and literature review - PubMed

Erythroderma combined with deeper dermal dermatophytosis due to Trichophyton rubrum in a patient with myasthenia gravis: first case report and literature review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37957543/

This case report shows that immunosuppressed patients with long histories of superficial mycoses tend to have a higher risk of developing invasive dermatophytic infections or disseminated fungal infections. Dermatologists should...

A rare case of erythroderma and deeper dermal dermatophytosis due to Trichophyton rubrum in a myasthenia gravis patient highlights the risk of invasive fungal infections in immunosuppressed individuals.

  • Saved

1yr
Emerging Myositis Treatments and Targeted Therapies – Insights from IgNS 2024

In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.

  • Saved

1yr
Emerging Myositis Treatments and Targeted Therapies – Insights from IgNS 2024

In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.

  • Saved

1yr
Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy - PubMed

Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38117543/

gMG has a physical, mental, and social impact, resulting in a considerable burden of disease and substantially decreased QoL, despite standard treatments. The availability of novel, targeted treatments that influence...

Generalized myasthenia gravis (gMG) presents management challenges; new therapies and standardized assessments can improve patient outcomes, optimize treatment, and enhance quality of life through personalized approaches and novel biomarkers.

  • Saved

1yr
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) - PubMed

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+) - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39227284/

ADAPT-SC (NCT04735432) was designed to evaluate noninferiority of subcutaneous (SC) efgartigimod PH20 to intravenous (IV) efgartigimod in participants with generalized myasthenia gravis (gMG). ADAPT-SC+ (NCT04818671) is an open-label extension study...

The ADAPT-SC and ADAPT-SC+ studies confirm that subcutaneous efgartigimod PH20 is noninferior to intravenous efgartigimod, demonstrating long-term safety and efficacy in treating generalized myasthenia gravis.